Jane Street Group LLC Purchases 111,917 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Jane Street Group LLC increased its holdings in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 63.7% in the third quarter, HoldingsChannel reports. The firm owned 287,717 shares of the company’s stock after buying an additional 111,917 shares during the period. Jane Street Group LLC’s holdings in Lyell Immunopharma were worth $397,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of LYEL. GSA Capital Partners LLP boosted its holdings in shares of Lyell Immunopharma by 1,285.5% during the third quarter. GSA Capital Partners LLP now owns 354,815 shares of the company’s stock worth $490,000 after acquiring an additional 329,205 shares during the period. State Street Corp grew its position in Lyell Immunopharma by 1.9% in the third quarter. State Street Corp now owns 3,889,553 shares of the company’s stock valued at $5,368,000 after acquiring an additional 71,233 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Lyell Immunopharma by 14.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 553,163 shares of the company’s stock valued at $802,000 after acquiring an additional 69,712 shares during the last quarter. Erste Asset Management GmbH bought a new stake in Lyell Immunopharma during the 3rd quarter worth approximately $82,000. Finally, American Century Companies Inc. grew its position in shares of Lyell Immunopharma by 18.1% in the 2nd quarter. American Century Companies Inc. now owns 279,425 shares of the company’s stock valued at $405,000 after buying an additional 42,752 shares during the last quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on LYEL. Bank of America downgraded Lyell Immunopharma from a “buy” rating to an “underperform” rating and dropped their price objective for the company from $6.00 to $1.00 in a research note on Wednesday, October 30th. HC Wainwright reissued a “neutral” rating and set a $1.00 price target on shares of Lyell Immunopharma in a research report on Tuesday, November 12th.

Lyell Immunopharma Stock Down 2.1 %

NASDAQ LYEL opened at $0.66 on Wednesday. Lyell Immunopharma, Inc. has a 12-month low of $0.58 and a 12-month high of $3.26. The company’s 50 day moving average is $0.89 and its 200-day moving average is $1.22. The firm has a market cap of $193.85 million, a P/E ratio of -0.84 and a beta of -0.35.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.03. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The company had revenue of $0.03 million for the quarter. Equities analysts expect that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.